NCT04827719View on ClinicalTrials.gov

BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

January 13, 2025

Study Completion Date

January 13, 2025

Conditions
Myelodysplastic SyndromesAcute Myeloid Leukemia
Interventions
DRUG

BST-236

Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)

Trial Locations (17)

13009

Institut Paoli Calmettes, Marseille

25030

CHU Besançon - Hôpital Jean Minjoz, Besançon

30029

CHU NIMES Caremeau, Nîmes

31100

CHU Toulouse - IUCT Oncopole, Toulouse

33604

CHU de Bordeaux Haut-Lévèque, Bordeaux

35033

Hôpital Pontchaillou, Rennes

38700

CHU de Grenoble, Grenoble

42270

Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez

44093

CHU Nantes - Hôtel Dieu, Nantes

49100

CHU d'Angers, Angers

72037

CH Le Mans, Le Mans

75010

Hôpital Saint Louis, Paris

80054

CHU Amiens, Amiens

86021

CHU de Poitiers, Poitiers

87042

CHRU de Limoges - Hôpital Dupuytren, Limoges

76 038

Centre Henri Becquerel, Rouen

06200

CHU de Nice - Hôpital Archet 1, Nice

All Listed Sponsors
lead

Groupe Francophone des Myelodysplasies

OTHER